Word: asco
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...molecular tool that will allow clinicians to select those patients who do not require chemotherapy at all," says Dr. David Kerr, a University of Oxford professor of cancer medicine, who led the study and will present its results at the annual meeting of the American Society of Clinical Oncologists (ASCO) in Orlando at the end of May. "It will empower some patients to be cured with surgery alone...
...screen can stratify patients by the likelihood of their cancer coming back, they might be more comfortable deciding whether to begin chemotherapy. "This is another piece of information that can guide the discussion physicians have with patients about their treatment options," says Dr. Richard Schilsky, president of ASCO and a cancer physician at the University of Chicago. And any such landmarks in that conversation are certainly welcome...
...cancer, it's easy to forget that sometimes the most effective defense can be the simplest. Despite all the gadgets that modern medicine has to image, diagnose and track a tumor, there is an easier way to go about things. Researchers at the American Society of Clinical Oncology (ASCO) conference in Chicago reported earlier this month that the best way to figure out how a cancer is progressing is to draw a little blood...
Even without such sophisticated genetic work, doctors can now learn more about how treatment is progressing simply by tallying the number of circulating cancer cells and better understanding what that head count means. At the ASCO conference, researchers from the U.S., Britain and the Netherlands reported that after about a month of treatment, patients who had advanced prostate and colon cancers and lower circulating cell counts survived an average of twice as long as those who had higher levels. More cells in the blood could be a sign that the drugs are not working and that it's time...
...asked Dr. Branimir Sikic, a professor at Stanford University School of Medicine who chaired the committee that designed ASCO's program. "It's correct that there were more Phase I studies in the clinical science symposia," he told me. "And we did that deliberately. It was a way to inform both practicing [cancer doctors] and clinical researchers about early data and the scientific background of new targets. We now have a huge amount of scientific research and much more knowledge in depth of why we should be targeting a particular gene or protein and how these drugs might work...